The Indicator from Planet Money · Friday, September 25, 2026
Approximately 11% of large employers either stopped covering GLP-1 medications like Ozempic and Zepbound last year or are considering doing so for next year, according to benefits consulting firm Mercer. While some executives see these drugs as a long-term health investment, their high cost is straining company budgets. Bank of America, for example, spends $250 million annually on these medications, representing over 10% of its healthcare budget.
“This is the number of large employers who dropped GLP1 coverage from their health plans last year, or they're strongly considering it for next year.”
“Bank of America CEO Brian Moynihan told CNBC that the company spends about $250 million a year on GLP1s.”
“But in the nearer term, it is incredibly expensive and healthcare costs are growing up generally.”